MYOF — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL31519075	1.00	2/20
SCHEMBL31519091	0.98	2/20
SCHEMBL31519121	0.98	2/20
SCHEMBL31519102	0.95	2/20
SCHEMBL31519107	0.91	2/20
SCHEMBL31519105	0.89	2/20
SCHEMBL31519117	0.86	2/20
SCHEMBL31519108	0.85	2/20
SCHEMBL31519090	0.85	2/20
SCHEMBL31519103	0.85	2/20
SCHEMBL31519097	0.84	2/20
SCHEMBL31519112	0.84	2/20
SCHEMBL31519074	0.84	2/20
SCHEMBL31519083	0.84	2/20
SCHEMBL31519087	0.83	2/20
SCHEMBL31519089	0.83	2/20
SCHEMBL31519094	0.83	2/20
SCHEMBL31519110	0.83	2/20
SCHEMBL31519114	0.83	2/20
SCHEMBL31519092	0.82	2/20

Clinical trials — most relevant to MYOF by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Deflazacort in Dysferlinopathies	PHASE2/PHASE3	COMPLETED
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.	PHASE1/PHASE2	RECRUITING
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy	EARLY_PHASE1	RECRUITING
Influence of Sarcopenia on the Course of the Diseases	nan	RECRUITING
Observational Cohort Study of Dysferlinopathy in China	nan	COMPLETED
ACTLIFE: is Active Life-style Enough?	nan	UNKNOWN
Clinical Outcome Study for Dysferlinopathy	nan	UNKNOWN
Transcutaneous Functional Magnetic Muscle Stimulation in Critically Ill	nan	UNKNOWN
Myostatin and Irisin Levels in Predicting the Outcome of Patients With Systemic Inflammation: A Prospective Observational Study	nan	COMPLETED
Molecular and Genetic Studies of Congenital Myopathies	nan	RECRUITING
High-definition Surface Electromyography Markers for the Diagnosis of Sarcopenia	nan	RECRUITING
Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma	nan	RECRUITING
High-definition Surface Electromyography Markers for the Diagnosis and Monitoring of Sarcopenia	nan	RECRUITING
Skeletal Muscle Regeneration in Survivors of Critical Illness: How to Prevent Satellite Cell Failure?	nan	RECRUITING
The Effect of Blood Flow Restriction (Bfr) Exercise on Acute Systemic Myokine Levels in Healthy Trained Men	nan	UNKNOWN
Characteristics of Nondystrophic Myotonias	nan	COMPLETED
Myotubular and Centronuclear Myopathy Patient Registry	nan	RECRUITING
Muscle Tissue Bank for Muscular Dystrophy	nan	COMPLETED
The Relationship Between Myonectin Concentration and the Course of ST-segment Elevation Myocardial Infarction	nan	UNKNOWN
Natural History Study for Patients With Nemaline Myopathy in Belgium	nan	NOT_YET_RECRUITING
GDF-15 as a Biomarker for Mitochondrial Disease	nan	COMPLETED
Beta-Hydroxy-Beta-Methylbutyrate Supplementation and Physical Activity in Liver Cirrhosis: a Controlled Trial	nan	UNKNOWN
Chronic Muscle Disuse in the Elderly	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Exploring Novel Biomarkers of ICU-AW in Mechanically Ventilated Children at the Molecular Level	nan	ENROLLING_BY_INVITATION
Phenotype - Genotype Correlation in a Sample of Egyptian Patients With Congenital Myopathies and Congenital Muscular Dystrophies	nan	RECRUITING
Effect of Exercise on the Human Skeletal Muscle Phosphoproteome	nan	COMPLETED
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	nan	COMPLETED
Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations	nan	UNKNOWN
Reduction of Muscle Catabolism Through Brain Activation in Burn Patients	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MYOF binder may also engage these)

Protein	Name	Similarity
Q69ZN7	—	1.000	Q69ZN7 →
A0AB32U2W5	—	0.997	A0AB32U2W5 →
O75923	—	0.996	O75923 →
B3DLH6	—	0.996	B3DLH6 →
A6QQP7	—	0.992	A6QQP7 →
Q9ESD7	—	0.990	Q9ESD7 →
Q2WGJ9	—	0.990	Q2WGJ9 →
E0CZ42	—	0.988	E0CZ42 →
A0AVI2	—	0.987	A0AVI2 →
P0DM40	—	0.984	P0DM40 →
A1ZBD6	—	0.983	A1ZBD6 →
Q9H1H9	—	0.983	Q9H1H9 →
NFKB1	Nuclear factor NF-kappa-B p105 subunit	0.981	landscape →
Q2KHZ2	—	0.981	Q2KHZ2 →
KDM5B	Lysine-specific demethylase 5B	0.981	landscape →
Q12466	—	0.981	Q12466 →
Q9EQW7	—	0.980	Q9EQW7 →
F4J8C6	—	0.980	F4J8C6 →
Q94CF0	—	0.980	Q94CF0 →
Q8BX57	—	0.980	Q8BX57 →
Q3UMY5	—	0.980	Q3UMY5 →
P31669	—	0.980	P31669 →
Q69ZS7	—	0.980	Q69ZS7 →
Q17388	—	0.980	Q17388 →
Q5ZMN2	—	0.980	Q5ZMN2 →
P43125	—	0.980	P43125 →
Q6AXM7	—	0.980	Q6AXM7 →
A1ZAJ2	—	0.980	A1ZAJ2 →
Q6DIP5	—	0.980	Q6DIP5 →
Q5XHF8	—	0.980	Q5XHF8 →